Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

GSK / 213823

Trial Overview

Official Title

A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD-L1-high NSCLC

 

Study Purpose

This study will test new combination of experimental drugs, dostarlimab + belrestotug, which have not yet been approved by the FDA.  The study will also evaluate the activity of pembrolizumab given in combination with placebo in lung cancer. Pembrolizumab has been approved by the FDA to treat the type of lung cancer you have been diagnosed with.

Diagnosis

Non small cell lung cancer

Eligibility

No prior treatment for lung cancer.  Your disease must be locally advanced, unresectable, or metastatic and be positive for PDL-1 (a tumor marker test) with a high score of 50% or more.  This study is only applicable to current or former smokers. 

 

Intervention

New experimental drugs dostarlimab and belrestotug used together and compared to pembrolizumab alone

 

For more information, go to the link below:

https://clinicaltrials.gov/study/NCT06472076?term=213823&rank=1

 

Key Participation Requirements
Trial Location(s)
Methodist Estabrook Cancer Center
Gender
Male/Female
Age
19 and older
Enrollment Status
Pending
Phase
Phase III
Methodist Health System Trial Code
213823